# US 2010/0137836 A1 · Storage and Dispensing Devices for Administration of Oral Transmucosal Dosage Forms

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0137836 A1
- Document ID: US20100137836A1
- Status: Published application
- Kind: A1
- Application number: 12/521,983
- Filed: 2007-12-28
- Published: 2010-06-03
- Earliest claimed: 2006-01-06
- Assignees: AcelRx Pharmaceuticals, Inc.
- Inventors: Pamela Palmer; Andrew I. Poutiatine; Charles Rampersaud; Bruce Edwards; Edmond Chiu; Thomas Schreck; Stelios Tzannis; Larry Hamel
- Web page: https://patentgrep.com/patent/US20100137836A1

## CPC

- A61K 9/20: Pills, tablets, {discs, rods (A61K9/0004, A61K9/0007, A61K9/0056, A61K9/0065 take precedence; for reconstitution of a drink A61K9/0095)}
- A61J 7/0038: {Straws}
- A61J 7/0053: {Syringes, pipettes or oral dispensers}
- A61J 7/0481: {working on a schedule basis}
- A61K 9/006: {Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays}
- A61K 9/2009: {Inorganic compounds}
- A61K 9/2018: {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}
- A61K 9/2031: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers}
- A61K 9/2072: {characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms (A61K9/0004, A61K9/0056, A61K9/0065 take precedence)}
- A61K 31/4535: containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
- A61M 15/00: Inhalators {(drug delivery in endotracheal tubes A61M16/04)}
- A61M 15/008: {Electronic counters}
- A61M 15/0081: {Locking means}
- A61M 15/0083: {Timers}
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- G07F 17/0092: {for assembling and dispensing of pharmaceutical articles (medical dispensers for private use, A61J7/00)}
- H01Q 1/2208: {associated with components used in interrogation type services, i.e. in systems for information exchange between an interrogator/reader and a tag/transponder, e.g. in Radio Frequency Identification [RFID] systems (methods or arrangements for sensing record carriers, e.g. for reading patterns G06K7/00; record carrier for use with machines and with at least a part designed to carry digital markings G06K19/00)}
- A61J 7/0418: {with electronic history memory}
- A61J 7/0445: {for preventing drug dispensing during a predetermined time period}
- A61J 2200/30: Compliance analysis for taking medication
- A61M 2205/276: preventing unwanted use
- A61M 2205/3561: local, e.g. within room or hospital
- A61M 2205/3584: using modem, internet or Bluetooth®
- A61M 2205/3592: using telemetric means, e.g. radio or optical transmission
- A61M 2205/52: with memories providing a history of measured variating parameters of apparatus or patient
- A61M 2205/583: by visual feedback
- A61M 2205/6054: Magnetic identification systems
- A61M 2205/609: Biometric patient identification means
- A61M 2209/086: Docking stations
- G07C 9/22: in combination with an identity check of the pass holder
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61J: CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G07F: COIN-FREED OR LIKE APPARATUS (coin sorting G07D3/00; coin testing G07D5/00; {handling coins or paper currencies apart from payment activated apparatus G07D; payment architectures, schemes or protocols G06Q20/00})
- H01Q: ANTENNAS, i.e. RADIO AERIALS (radiators or antennas for microwave heating H05B6/72)
- G07C: TIME OR ATTENDANCE REGISTERS; REGISTERING OR INDICATING THE WORKING OF MACHINES; GENERATING RANDOM NUMBERS; VOTING OR LOTTERY APPARATUS; ARRANGEMENTS, SYSTEMS OR APPARATUS FOR CHECKING NOT PROVIDED FOR ELSEWHERE

## Abstract

Compositions, methods and systems for oral transmucosal administration of small volume sufentanil-containing drug dosage forms to a subject using a drug dispensing device are disclosed. The drug dispensing device may provide for administration of multiple doses, a single dose at a time or be a single dose applicator (SDA).

## Claims

### Claim at position 1

1-20. (canceled)

### Claim 21

A method for administration of individual bioadhesive small volume sufentanil-containing solid drug dosage forms for oral transmucosal uptake by a subject using a drug dispensing device, comprising:
a. obtaining a hand-held device comprising one or more bioadhesive solid drug dosage forms, each solid dosage form comprising an amount of sufentanil selected from the group consisting of 5 mcg, 10 mcg, 15 mcg, 20 mcg, 30 mcg, 40 mcg, 50 mcg, 60 mcg, 70 mcg, 80 mcg and 100 mcg, and having a volume of less than 40 microliters or a mass of less than 40 mg;
b. inserting the dispensing end of said device into the mouth of said subject; and
c. dispensing an individual bioadhesive solid drug dosage form through the dispensing end of the device, wherein the bioadhesive solid dosage form is placed on an oral mucosal membrane of said subject and sufentanil is absorbed via the oral mucosa with minimal gastrointestinal (GI) uptake.

### Claim 22 (depends on 21)

The method according to claim 21, wherein said drug dispensing device is a hand-held device.

### Claim 23 (depends on 21)

The method according to claim 21, wherein said oral mucosal membrane is a sublingual or buccal membrane.

### Claim 24 (depends on 21)

The method according to claim 21, wherein the dispensing end of said device has a proboscis comprising a shroud for placing said solid dosage form and said shroud includes a means to prevent or retard saliva and other moisture ingress into said device, wherein said dosage forms remain dry prior to placement on said oral mucosal membrane.

### Claim 25 (depends on 21)

The method according to claim 21, wherein said device comprises a lock-out feature for setting a lock-out time and wherein a solid drug dosage form cannot be dispensed from said device during said lock-out time.

### Claim 26 (depends on 25)

The method according to claim 25, wherein said lock-out time is a fixed time lock-out interval, a predetermined lock-out interval, a predetermined variable lock-out interval, a lock-out interval determined by an algorithm or a variable lock-out interval communicated to the device from a remote computer, docking station or other device.

### Claim 27 (depends on 26)

The method according to claim 26, wherein said lock-out interval is 20 minutes.

### Claim 28 (depends on 21)

The method according to claim 21, wherein said dispensing device comprises a pre-filled disposable cartridge configured to hold one or more solid drug dosage forms.

### Claim 29 (depends on 28)

The method according to claim 28, wherein said pre-filled disposable cartridge holds 40 individual solid drug dosage forms or sufficient drug dosage forms to provide 48 to 72 hours of treatment.

### Claim 30 (depends on 21)

The method according to claim 21, wherein said cartridge includes a smart cartridge recognition system comprising a physical keyed feature on the cartridge, an optically detected feature or pattern, a bar code on the cartridge, a magnetic tag on the cartridge, an RFID tag on the cartridge, an electronic microchip on the cartridge, or a combination thereof.

### Claim 31 (depends on 21)

The method according to claim 21, wherein said dispensing device further comprises a patient identification means.

### Claim 32 (depends on 31)

The method according to claim 31, wherein said patient identification means is a radio frequency identification (RFID) reader configured to couple with a matching RFID tag on a patient to be identified and said dispensing device is unlocked or enabled when the RFID reader on the dispensing device detects a matching RFID tag on a patient.

### Claim 33 (depends on 21)

The method according to claim 21, wherein said dispensing device further comprises one or more of a means for: (i) recording dosing or use history, (ii) recording dosing and use history, (iii) a means to view or download dosing or use history, or (iv) a means to view or download dosing and use history.

### Claim 34 (depends on 23)

The method according to claim 23, wherein erosion of said solid dosage form is complete in from about 30 seconds to about 30 minutes following the dispensing of said solid dosage form on the sublingual membrane.

### Claim 35 (depends on 23)

The method according to claim 23, wherein a single sublingual administration of said solid dosage form to a subject results in a bioavailability of at least 50%.

### Claim 36 (depends on 23)

The method according to claim 23, wherein repeated sublingual administration of said dosage forms to a subject, results in a bioavailability that is greater than the bioavailability following a single sublingual administration to said subject.

### Claim 37 (depends on 23)

The method according to claim 23, wherein a single sublingual administration of said dosage form to a subject results in a Tmax with a coefficient of variation of less than 40%.

### Claim 38 (depends on 23)

The method according to claim 23, wherein the difference between the Tmax following repeated sublingual administration and the time of the previous sublingual administration is shorter than the Tmax following a single sublingual administration to said subject.

### Claim 39 (depends on 23)

The method according to claim 23, wherein an amount of drug selected from the group consisting of at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98% and at least 99% of the total amount of drug in said dosage form is absorbed via the sublingual route.

### Claim 40 (depends on 21)

The method according to claim 21, for treating pain in a subject, wherein following administration of said dosage form, pain relief is evident in said subject.
